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Neisseria meningitidis causes severe invasive meningococcal 
diseases (IMDs) in humans including meningitis and septice-
mia, responsible for serious clinical conditions and leading to 
life-long disabilities and death. Serogroup B dominates IMDs 
burden in Italy, accounting for over 60% of total cases. On 
January 2013 the European Medicine Agency (EMA) licensed 
the first serogroup B meningococcal (MenB) vaccine in Europe. 
A number of European countries and Regions have introduced 
the new MenB vaccine in their immunization schedule, including 
Italy. In this paper we present the state of art, related critical 
issues and future perspectives of MenB vaccine introduction in 
Italy, in the context of the most recent available epidemiologi-
cal data. In particular, we systematically assess the ongoing 
processes in the 8 Italian regions and one autonomous prov-
ince that have already introduced MenB vaccine. With the new 
2014-2018 National Vaccine Prevention Plan including active 
MenB vaccine offer about to be adopted, it is of fundamental 
importance to gather further evidence on MenB vaccine clinical 
effectiveness, duration of protection and cost-effectiveness. Ital-
ian regions are called to organize and manage MenB immuniza-
tion programs. Careful consideration will need to be devoted 
on timing, doses, and co-administration with other vaccines but 
also to economic assessments and strengthened communication 
to the general public. Our data will help to plan, implement and 
evaluate MenB immunization programmes in other Italian and 
international settings.
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Summary
Background
Neisseria meningitidis (meningococcus) causes severe 
invasive meningococcal diseases (IMDs) in humans in-
cluding meningitis and septicemia, responsible for seri-
ous clinical conditions and leading to life-long disabili-
ties and death [1]. It is estimated that between 10% and 
14% of cases of IMD are fatal, and that up to 30% of 
survivors suffer from long-term sequelae [2, 3]. There 
are 13 identified sereotypes of meningococcus, with six 
(A, B, C, X, W-135 and Y) being responsible for over 
90% of severe meningitis and septicemia cases [4]. The 
distribution of meningococcus sereotypes is setting–spe-
cific. Serogroup A is mainly distributed in the Sub-Sa-
haran African countries of the meningitis belt where it 
causes around 85% of IMDs. Serogroup X, previously 
a rare cause of sporadic meningitis, has been responsi-
ble for outbreaks between 2006 and 2010 in the African 
region [5, 6]. The meningitis belt is the area where the 
highest burden of IMDs occurs with 14317 cases and 
1304 deaths reported in 2014 [7]. 
In Europe, the USA and other industrialised regions, 
serogroups B and C are the major cause of IMDs [8]. 
In Europe good surveillance data is available in most 
countries and implementation of meningococcal immu-
nization programs have largely contributed to decreas-
ing endemic rates [9]. The most recent available surveil-
lance data refers to 2012 with 3,463 reported IMDs, this 
corresponding to an incidence of 0.68 cases per 100,000 
population, higher in children under one year of age 
(11.4/100,000) and between one and four years of age 
(3.7/100,000). The overall case fatality rate (CFR) was 
7.9% and meningitis was the clinical presentation in 
43% of cases [8].  
Meningococcal disease is a vaccine preventable disease. 
There are several registered vaccines: a meningococcal 
A conjugate vaccine, C conjugate vaccines, tetravalent 
A, C, Y and W conjugate vaccines and meningococcal 
polysaccharide vaccines [10]. In Europe, serogroup C 
conjugate vaccination (MCC) implementation has had 
a major impact on the declining incidence of serogroup 
C meningitis [11]. In 2012, serogroups B and C were re-
sponsible for, respectively, 68% and 17% of confirmed 
IMDs cases in the EU [8]. Since the introduction of sero-
group C conjugate vaccination (MCC) Meningococcus 
B had emerged as a relatively important cause of IMD in 
Europe, this due to the lack of preventative measures for 
this serogroup [12]. On 14 January 2013 the European 
Medicine Agency (EMA) licensed the first serogroup 
B meningococcal vaccine in Europe. A number of Eu-
ropean countries and Regions have introduced the new 
MenB vaccine in their immunization schedule, includ-
ing Italy. In the United States the first Meningococcal 
Group B vaccine was licensed by the Food and Drug 
administration in 2014 Vaccine [13].
General aim of the present study is to describe the in-
troduction of the MenB vaccine in Italy, presenting the 
state of art, related critical issues and future perspec-
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tives. In particular, specific objectives are: i) to describe 
the technical documents, decisions and polices taken at 
the national level and ii) to systematically assess the on-
going processes in the 8 Italian regions and one autono-
mous province that have already introduced the MenB 
vaccine in the Regional immunization schedules.
The new Meningococcal B vaccine
As introduced above, a new vaccine for the prevention 
of serogroup B meningococcal (MenB) disease is now 
available in Europe (4CMenB) [14, 15]. In the past, the 
antigenic diversity of the meningococcal surface pro-
teins had been the main limitation in the design of broad-
ly protective meningococcal vaccines, as well as the fact 
that the polysaccharide of serogroup B fails to stimulate 
the production of antibodies (phenomena of immune tol-
erance) MenB vaccine was developed through the ‘re-
verse vaccinology’ technique, which has been applied 
for the first time to develop the MenB vaccine [16] and 
allows the production of vaccines from genome-derived 
antigens. In fact, it applies bioinformatic tools to com-
prehensively screening of pathogens’ genome data for 
surface-expressed proteins, in order to select candidate 
vaccine antigens. Proteins likely to be used as vaccine 
antigens are identified and further tested for immuno-
genicity on animal models [17]. In the case of MenB, 
the genome sequence of the virulent MenB strain MC58 
was analysed (i.e The MenB genome was sequenced). 
Nearly 600 open reading frames were selected; from 
these, 350 candidate antigens were expressed in Escher-
ichia coli, purified and used to immunize mice. Subse-
quent screening of the mice sera revealed 91 surface-
exposed proteins that induced bactericidal antibodies in 
vivo  [18]. This step-by-step elimination, based on the 
ability to induce broad protection in infant rat or mouse 
models, led to the identification of the antigens now 
included in the 4CMenB vaccine formulation. In other 
words, the reverse vaccinology strategy identified a set 
of proteins that had the characteristic for being effective 
vaccines’ antigens: accessible to the immune system, 
immunogenic, inducing a protective response, present in 
all strains, and with minimal sequence variation [18, 19].
The 4CMenB contains the following four compo-
nents [19]:
•	 The Neisserial adhesion protein (NadA);
•	 The Neisseria Heparin Binding Antigen (NHBA) 
fused with the Neisserial Antigens GNA1030;
•	 The factor H binding protein (fHbp) fused with the 
Neisserial Antigens GNA2091;
•	 Outer membrane vesicles (OMV)
4CMenB is indicated for active immunisation of indi-
viduals from 2 months of age and older, against invasive 
meningococcal disease caused by Neisseria meningitidis 
group B. It was licensed in Europe (European Medicine 
Agency - EMA, 2013) [20], in Australia (Therapeutic 
Goods Administration - TGA, 2013), in USA (Food and 
Drug Administration - FDA, 2015) in Canada (2013) 
and Chile [14, 15]. In the United States, also another 
MenB vaccine was licensed by FDA in 2014 (rLP2086 
vaccine) [21].
Clinical trials have been carried out in the context of the 
vaccine registration process and some data are avail-
able on 4CMenB immunogenicity and safety. No stud-
ies have been conducted so far to test clinical efficacy 
and vaccine efficacy has been inferred by demonstrating 
the induction of serum bactericidal antibody response to 
vaccine antigens [20, 22-25].
MenB vaccine introduction in other 
countries: an update
As the new MenB vaccine has been licensed in several 
countries and scientific evidence is accumulating on its 
efficacy and safety, a number of countries are in the pro-
cess of evaluating the introduction of MenB vaccine in 
their immunization schedule (Tab. I).
To our knowledge, the United Kingdom is the only 
country where universal 4CMenB vaccination has been 
recommended. The Joint Committee on Vaccination and 
Immunization (JCVI) published a document in March 
2014 recommending to offer to offer the MenB vaccine 
to children at 2, 4 and 12 months (2+1 doses schedule). 
As the JCVI states, this recommendation depends on se-
curing a cost-effective price for the vaccine [26].
In France, Germany, Spain, the USA as well as the UK, 
MenB vaccine is recommended on an individual basis to 
high-risk subjects and during outbreaks [26-29].
Other countries including Canada, Ireland and Belgium 
National Immunization Committees have not yet pro-
duced recommendations and are waiting to gather rele-
vant epidemiological and economic data to support their 
decisions.
National Immunization Committees in Spain and Ger-
many have recently concluded that there is not enough 
available data on vaccine efficacy and economic analy-
sis to support the introduction of universal MenB immu-
nization in national immunization schedules, this also 
considering that MenB meningitis incidence is decreas-
ing in those countries [28, 29].
Setting-specific predictive models on the epidemiologi-
cal impact of MenB vaccine introduction and cost-effec-
tives analysis have been carried out in France, this mod-
el allowed to evaluate different vaccine strategies [27].
In decentralized health systems – as we will outline 
for Italy – some regions but not others have introduced 
MenB vaccine in their immunization schedule, includ-
ing Saxony in Germany and Quebec in Canada [30].
The Italian setting
Epidemiology of Meningococcal diseases in 
Italy
To describe IMDs epidemiology in Italy, two sources 
of data are used: i) the National Surveillance System of 
Invasive Bacterial Diseases (MIB), coordinated by the 
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Italian Institute of Health [31] and ii) the National hospi-
tal discharge records administrative register (SDO).
Surveillance IMDs data in Italy is available from the 
MIB system for the periods 1994-2006, 2007-2010 and 
2011-2015 [32]. The most recent MIB data were up-
dated in March 2015 [32]. In 2013 in Italy 172 cases 
of invasive meningococcal disease were reported, this 
corresponding to an incidence rate of 0.29 cases per 
100,000, slightly higher as compared to previous years 
(0,23/100,000 in 2012 and 0,25/100,000 in 2011). IMD 
incidence in Italy is among the lowest in Europe [8].
IMDs’ incidence is higher in the age group 0-4 years 
(1.75/100,000 in 2013) and in particular in the first year 
of life (4.01/100,000 in 2013), this mirroring IMDs epi-
demiology of most high-income countries. Nearly 50% 
of IMDs cases are sepsis or meningitis/sepsis, the per-
centage being higher children under 5 years of age (76% 
in 2013).  A relatively stable trend is reported in 2011-
2013 in all regions apart from 4 regions (Apulia, Lom-
bardy, Marche, Tuscany) where number of cases slightly 
increased over the years and the Veneto region where it 
decreased. IMDs’ Mortality data is derived from nation-
al mortality data and available for the period 2003-2010 
where 122 IMDs deaths were reported [33].
In Italy Meningococcus B is the most common notified 
serogroup (46, 50 and 63% of the total of strains typed 
in 2011, 2012 and 2013), followed by meningococcus 
C (33, 17 and 17% of the strains typed in 2011, 2012 
and 2013) and meningococcus Y (16, 17 and 13% of the 
strains typed in 2011, 2012 and 2013), this distribution 
remaining constant over the years. Of concern, the per-
centage of notified infection for which serogroup info 
Tab. I. recommendations and positions of selected european countries on menB vaccine.
Country Reccomendations
MenBIMDIncidence 
(by age of group)
Country Reccomendations
MenBIMDIncidence 
(by age of group)
Belgium
Currently not reccomend-
ed. The Superior health 
Council is currently assess-
ing the available evidente 
on the topic
relative to 2011 Total: 0.8/100,000 <1 year: 10.8/100,000
1-4 years: 
4.3/100,000
France
Not routinely recommend-
ed for children and ado-
lescente. recommended 
for high-risk subjects and 
durino outbreaks
relative to 2011 Total: 0.6/100,000 <1 year: 8.4/100,000
1-4 years: 
2.8/100,000
germany
Currently not recommend-
ed. It may be recommend-
ed for people at increased 
risk of Imd, but the decision 
to vaccinate shold be based 
on individual considerations 
of risk/benefit
relative to 2012 Total: 0.3/100,000 <1 year: 5.9/100,000
1-4 years: 
1.7/100,000
Ireland
Ongoing evaluation. Cost 
effectiveness study in pro-
gress
relative to 2012 Total: 1.3/100,000 <1 year: 23.5/100,000
1-4 years: 
17.9/100,000
portugal Assessment in progress relative to 2011 Total: 0.3/100,000 <1 year: 17.8/100,000
1-4 years: 
2.7/100,000
United 
Kindgdom
reccommended condi-
tional on the vaccine being 
available at low cost. the 
vaccine should also be of-
fered to the same high-risk 
groups who are offered the 
ACWy vaccine.
relative to 2011 Total: 1.3/100,000 <1 year: 25.3/100,000
1-4 years: 
8.6/100,000
Spain
Currently not recommend-
ed. health authorities may 
consider whether to use 
the vaccine in case of out-
breaks and for immuno-
compromised patients.
relative to 2011 Total: 0.7/100,000 <1 year: 13.1/100,000
1-4 years: 
4.4/100,000
Canada Currently not recommended relative to 2012 Total: 0.23/100,000 <1 year: 6.2/100,000
1-4 years: 0.4 to 
1.4/100,000
United 
States
Currently it is recommend-
ed for individuale identi-
fied as being at greater risk 
of contracting Imd durino 
outbreaks
relative to 2012 Total: 0.06/100,000 <1 year: 1.24/100,000
1-4 years: 
013/100,000
Translated and adapted from: Istituto Superiore di Sanità (ISS): vaccinazione anti-meningococco B: dati ed evidenze disponibili per l’introduzione in nuovi 
nati e adolescenti. 2015 [33].
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is not available, is high (33% in 2013) and increased as 
compared to 2011 (23%) and 2012 (21%).   Although 
with fluctuations in incidence, serogroup B IMDs dis-
tribution over time (1994-2013) has been constantly 
greater as compared to serogroup C IMDs (except in the 
years 2004 and 2005), this being in line with the data 
from other European countries [8] from the literature, 
presents clear fluctuations of incidence over time. The 
number of cases of serogroup B between 1994 and 2012 
has always been greater than the number of cases by se-
rogroup C, except that in the years 2004 and 2005.
Comparing hospital discharge records data with Nation-
al IMDs’ surveillance system register allow to assess 
the latter’s detection rate, which is estimated to slightly 
underestimate IMDs’ burden in Italy [33]. In addition, 
the percentage of IMDs with no serotyping data, remains 
high at 20%. Furthermore, in 2013 the proportion of typ-
ified cases (67%) is lower than 2012 (79%) and 2011 
(77%).
Combining data on IMD cases derived from hospital 
discharge records with the serogroup distribution re-
ported by the IMD surveillance system, it is estimated 
that serogroup B IMD incidence in the period 2007-
2012 was 0,23/100,000, higher in the first year of life 
(3.44/100,000 in 2013) and in the 1-4 years age group 
(1.07/100,000 in 2013). In particular, 133 serogroup B 
IMDs were reported in 2007, of which 43 in children 
<5 years and 19 in children <1 year. The average im-
pact of serogroup B IMDs in Italy in 2007-2012 is es-
timated to be 5,194 DALY per year, with an average 
mortality impact of 4,817 years of life lost per year and 
average sequelae impact of 376 years with disabilities 
per year [33].
National-level immunization polices  
and guidance documents
In Italy, The National Vaccine Prevention Plan (PN-
PV) is the guidance document issued by the Ministry 
of Health that establishes immunization recommenda-
tions at the national level and sets national coverage tar-
gets with the overall aim of harmonizing immunization 
strategies among Italian regions. The 2012-2014 PNPV, 
published in February 2012 does not include recommen-
dations on 4CmenB [34].
In 2014 it was published the second edition of the “Life-
time immunization schedule” [35], a joint proposal for 
an immunization schedule issued by the four Italian 
scientific societies, historically involved in the study 
of vaccines and vaccination policies, namely: the Ital-
ian Society of Hygiene, Preventive Medicine and Public 
Health (SItI), the Italian Society of Paediatrics (SIP), the 
Italian Federation of Family Paediatricians (FIMP), and 
the Italian Federation of General Practitioners (FIM-
MG). The 2014 “Lifetime immunization schedule” rec-
ommends the introduction of universal 4CmenB immu-
nization with the 3+1 doses schedule at 3°-4°-6° months 
of age with a booster dose after 13 months of age. The 
“Lifetime immunization schedule” recommends also 
the use of MenB vaccine on an individual basis in at-
risk subjects as specified in the vaccine’s summary of 
product characteristics [20] and raises awareness on the 
importance of routinely vaccinating also adolescents 
against meningococcal disease [35].
While recommending the introduction of universal 
MenB immunization in Italy with a 3+1 doses schedule, 
the 2014 “Lifetime immunization schedule” leaves to 
regional health authorities the final decision on the best 
setting-specific immunization schedule to adopt. As for 
now the decision to include MenB vaccine in the im-
munization schedule is taken at the regional-level in a 
context where several regions are coping with deficit-
reduction plans.
Introduction of Meningococcal B vaccine  
in Italian Regional immunization schedules
Currently there are three types of meningitis vaccine 
available in Italy: the meningococcal polysaccharide 
tetravalent (A, C, Y and W-135) vaccine, the meningo-
coccal conjugate tetravalent (A, C, Y and W-135) vac-
cine and the Monovalent serogroup C conjugate vaccine.
Since 4CmenB was licensed by EMA and became avail-
able in Italy, eight Italian regions and one autonomous 
province have introduced it in their regional immuniza-
tion schedules as active immunization offer – free of 
charge for all children under one year of age. The eight 
regions are Apulia, Basilicata, Calabria, Friuli Venezia 
Giulia, Liguria, Sicily, Tuscany and Veneto [36]. Of 
them, five have implemented the 3+1 doses MenB im-
munization schedule and two the 2+1 doses one. The 
Autonomous Province of Bolzano has also implemented 
the 2+1 schedule [36, 37]. The MenB vaccine schedules 
in different Italian regions are schematized in Table II.
In particular, the region Apulia has been the first region 
to include the 3+1 doses universal MenB vaccine offer 
in the regional immunization schedule, legally formal-
ized in January 2014, added to the updated edition of 
the regional lifetime immunization schedule and imple-
mented starting with the 2014 birth cohort [38].
Similarly, the Basilicata and Tuscany regions adopted in 
February and October 2014, respectively, the 3+1 doses 
universal MenB vaccine [39-41] and implemented the 
new immunization programme starting from the 2014 
birth cohort. More recently, in January 2015, the regions 
Sicily and Liguria adopted the 2014 “Lifetime immu-
nization schedule” and introduced the MenB vaccine 
within the regional immunization schedules [42-44].
Two regions, Veneto and Friuli Venezia Giulia have in-
troduced MenB vaccine starting with the 2015 birth co-
hort and recommending the 2+1 doses schedule [45-47]. 
The Autonomous Province of Bolzano has introduced 
the MenB vaccine in the immunization schedule with 
the 2+1 dose approach for subjects between 3 and 15 
months of age [36, 37].
Also Calabria recently decided to introduce the vaccine 
against meningococcus B: since May 2015 the vac-
cine was included in the vaccination schedule with the 
scheme 3 + 1 doses, but timing of the third dose it is not 
clearly specified [48].
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Tab. II. menB vaccine schedules implemented in different Italian regions [36-48]. 
Region
3° 
Month
4° 
Month
5° 
Month
6° 
Month
7° 
Month
8°
Month
9° 
Month
13° 
Month
14° 
Month
15° 
Month
SChEdUlE 2 doSES+ 1 BooSTER
Autonomous 
province of 
Bolzano
Still to be decided  
(2 doses+1 booster)
Friuli venezia 
giulia
1° menB 
dose
2° menB 
dose
menB 
booster 
dose
veneto
1° menB 
dose
2° menB 
dose
menB 
booster 
dose
SChEdUlE 3 doSES + 1 BooSTER
Apulia
1° menB 
dose 76° 
day (after 
15 days 
from the 
adminis-
tratiin of 
hexavalent 
+ pCv13)
2° menB 
dose 
106° day 
(afrte 1 
month 
from the 
1° dose 
of menB 
vaccine)
3° menB 
dose 151° 
day (after 
month 
from the 
2° dose of 
menB vac-
cine)
menB 
booster 
dose (in 
co-ad-
minis-
tration 
with 
menC)
Basilicata
1° menB 
dose 75°-
90° day
2° menB 
dose 
135°-150° 
day
3° menB 
dose 
181°-210° 
day
menB 
booster 
dose after 
the 13° 
month
Calabria
1° menB 
dose 76° 
day
2° menB 
dose 
106° day
3° menB 
dose
menB 
booster 
dose
Liguria
1° menB 
dose 76° 
day
2° menB 
dose 
106° day
3° menB 
dose 151° 
day
menB 
booster 
dose
Sicily
1° menB 
dose 
(after 1 
month 
from the 
admin-
istration 
of hexa-
valent, 
pCv13 
and 
rota)
2° menB 
dose 
(after 1 
month 
from the 
admin-
istration 
of hexa-
valent, 
pCv13 
and rota
3° menB 
dose at 
7° or 8° 
month 
(after 1 
month 
from the 
adminis-
tration of 
2° menB 
dose)
3° menB 
dose at 
7° or 8° 
month 
(after 1 
month 
from the 
adminis-
tration of 
2° menB 
dose)
menB 
booste 
dose at 
15°-18° 
month 
(after 1 
month 
from 
the 
admin-
istra-
tion of 
mrrv)
Tuscany
1° menB 
dose 
76° day 
(15 day 
after the 
adminis-
tration of 
hexavalent 
+ pneu-
mo)
2° menB 
dose 
106° day 
(1 month 
after the 
1° menB 
vaccine)
3° menB 
dose 151° 
day (after 
1 month 
from the 
2 dose 
of hexa-
valent + 
pneumo)
menB 
booster 
dose
data derived from regional immunization schedules [36-48]
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discussion
The introduction of MenB vaccine in Italian regional 
immunization schedules rises several issues around: 1) 
the organization and management of immunization pro-
grammes; 2) health education and communication to the 
general population and, in particular, parents; 3) eco-
nomic sustainability in a context of deprived resources 
for the national health system.
Organization and management of 
immunization programmes
In the 2012-2014 National Vaccine Prevention Plan 
(PNPV) some general principles are outlined: a) the 
need of concentrating as much as possible the number 
of immunization sessions; b) the importance of avoid-
ing that vaccines’ co-administrations increase the risk 
of adverse effects; c) the urge of avoiding more than 2 
injections in the same immunization session and d) the 
importance of guarantying the economic sustainability 
of immunization offers [49]. In this context, it is easy 
to understand the organisational problems related to the 
introduction of the MenB vaccine in children’s immuni-
zation schedule. In fact, not only it requires to perform 
4 doses in a limited and early-in-life period (3-4 doses 
during the first year of age), but also there is some evi-
dence that MenB co-administration with other vaccines 
increase the risk of moderate to high fever [20].
As mentioned, the 2014 “Lifetime immunization sched-
ule” recommends the introduction of universal 4CmenB 
immunization with the 3+1 doses schedule at 3°-4°-6° 
months of age with a booster dose after 13 months of 
age [35]. This schedule, although has the unavoidable 
disadvantage of adding three additional immunization 
sessions in the first year of age, has the following ad-
vantages [35]:
•	 administration of the first 3 doses in a short time; 
•	 no changes to the current schedule for the other chil-
dren routine vaccinations; 
•	 administration of no more than two vaccines in a 
single session, minimizing the possibility of adverse 
events (fever);
•	 it allows to separately monitor any adverse events of 
the new vaccine;
•	 it makes it easier for parents to remember the next 
appointment.
When formulating a vaccine schedules some factors are 
to be taken into consideration, this including the age-
specific distribution of diseases, age group with the 
highest disease incidence, the disease’s clinical symp-
toms and complications, the vaccine’s indicated doses 
and duration of protection [31]. In light of this reasoning 
the 2014 “Lifetime immunization schedule” also pre-
sents the MenB 2+1 doses immunization schedule with 
vaccine administration at 7°-9° months of age with a 
booster dose at two years of age [35]. The 2+1 doses im-
munization schedule had the advantage – as compared to 
the 3+1 doses immunization schedule – of adding only 
two additional vaccine sessions in the first year of age. 
However, if the 2+1 schedule is not combined with the 
effect of herd immunity and – ultimately – decreasing 
MenB incidence, it would fail to prevent IMDs in the 
first months of age which is when the highest burden of 
IMDs is concentrated [35].
Health education and communication
Challenges related to motivating parents to have their 
children vaccinated against MenB is a threat to the suc-
cess of MenB immunization programmes. Low compli-
ance to 4CMenB vaccination by parents might be as-
sociated on one hand by the introduction of additional 
immunization sessions in the first year of age and on the 
other by lack of information [50] around the new MenB 
vaccine. The Italian Center for Social Studies and Poli-
cies (CENSIS) has recently conducted a survey on a rep-
resentative sample of 1,100 Italian parents (550 mothers 
and 550 fathers aged 22 to 55 years) with children from 
0 to 12 years (target population for MenB vaccine) to 
assess parents’ knowledge and attitudes towards IMDs 
and available vaccines, in particular MenB vaccine [51].
As emerges from the survey, 85.5% of parents report to 
be aware of meningococcal disease; among these 30% 
consider themselves to be adequately informed, espe-
cially parents with an high level of education. The main 
sources of information about meningitis and meningo-
coccal vaccination are paediatricians (48.8% and 33.9%, 
respectively). However, 33% of respondents report not 
to have received proper health education on the topic. In 
addition, although one third of parents consider to have 
accessed to all needed information, almost half (45%) 
wants to be more informed. The majority of respond-
ents (95%) believe that immunization campaigns target-
ing the general populations are necessary to educate and 
raise awareness on the benefits of MenB vaccination 
and to allow parents to take informed decisions. When 
specifically focusing on the new MenB vaccine, almost 
70% of parents is not aware of its existence, this percent-
age being higher among parents with lower education. 
When asked about MenB vaccine population target, 
23% report not to know it. Of crucial importance, half of 
the respondents do not know if MenB vaccine is avail-
able in their region of residence. More than half of the 
parents report their intention to vaccinate their children 
against meningococcus B, and if we add to this percent-
age 37.6% being ‘undecided’, the percentage of Italian 
parents not opposed to this new vaccine rises to about 
90% [51].
Economic issues
The introduction of new vaccines needs to follow trans-
parent criteria of efficacy, safety, economic sustainabil-
ity and public health prioritization [52]. Immunization 
schedules are proposed by experts in the field of clinical 
medicine, epidemiology and public health on the basis 
of the available scientific evidence and are then imple-
mented by policy makers also taking into consideration 
resources allocation and financial sustainability [53]. 
In context of deprived resources for the Nation Health 
system, economic sustainability of new immunization 
programmes should be carefully assessed. Taking into 
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consideration both the fact that serogroup B IMD inci-
dence is relatively low and that 4CmenB does not pro-
tect against all circulating strains (around 87% [33], the 
estimated cost per IMD case prevented is very high [54]. 
This consideration has stimulated a lively debate in the 
scientific community and among health authorities. As 
for now, Italian setting-specific cost-effectiveness and 
cost-benefit analysis on the introduction on 4CMenB are 
still scant [55].
Conclusions
The new National Vaccine Prevention Plan (PNPV) has 
been drafted in close consultation with Italian scientific 
societies and is about to be approved. It will likely in-
clude MenB immunization with an offer active and free 
of charge. This is a relevant step towards a comprehen-
sive immunization offer and a significant sign at the 
national level. The implementation of MenB immuniza-
tion programmes, the organizational details such as the 
calling methods and the organization of the vaccination 
services are still to be discussed and will be planned at 
the level of individual regions considering the overall re-
sources needed, the workforce of health services and the 
availability of different healthcare professionals groups 
(family paediatricians).
Compared to other vaccine-preventable diseases, the 
IMDs incidence in Italy is low; however, IMDs are as-
sociated with a high lethality rate and high risk of com-
plications. Serogroup B accounts for the vast majority of 
meningococcal infections in Italy 4CMenB vaccine has 
good immunogenicity profile against invasive meningo-
coccal disease B. Further evidence are needed and are 
currently being collected on the vaccine clinical effec-
tiveness, duration of protection and cost-effectiveness. 
4CMenB is under additional monitoring for the next five 
years and this will allow to collect detailed data on sus-
pected adverse reactions. We present updated data on 
the eight Italian regions that have already implemented 
4CMenB for the 2014 and 2015 birth cohorts taking into 
consideration IMDs burden in Italy. Our data will help 
to plan, implement and evaluate 4CMenB immunization 
programmes in other Italian setting. This will require 
careful consideration on timing, doses, and co-admin-
istration with other vaccines but also further economic 
assessments and strengthened efforts by institutions and 
scientific societies to promote health education and good 
communications among the population [56-59].
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